'Stem-cell tourism' needs
tighter controls, say medical experts
Send a link to a friend
[July 06, 2017] LONDON
(Reuters) - Stem-cell tourism involving patients who travel to
developing countries for treatment with unproven and potentially risky
therapies should be more tightly regulated, international health experts
said on Wednesday.
|
With hundreds of medical centers around the world claiming to be
able to repair damaged tissue in conditions such as multiple
sclerosis and Parkinson's disease, tackling unscrupulous advertising
of such procedures is crucial.
These therapies are advertised directly to patients with the promise
of a cure, but there is often little or no evidence to show they
will help, or that they will not cause harm, the 15 experts wrote in
the journal Science Translational Medicine.
Some types of stem cell transplant – mainly using blood and skin
stem cells – have been approved by regulators after full clinical
trials found they could treat certain types of cancer and grow skin
grafts for burns patients.
But many other potential therapies are only in the earliest stages
of development and have not been approved by international
regulators.
"Stem cell therapies hold a lot of promise, but we need rigorous
clinical trials and regulatory processes to determine whether a
proposed treatment is safe, effective and better than existing
treatments," said one of the 15, Sarah Chan of Britain's University
of Edinburgh.
[to top of second column] |
The experts called for global action, led by the World Health
Organization, to introduce controls on advertising and agree
international standards for the manufacture and testing of cell and
tissue-based therapies.
"The globalization of health markets and the specific tensions
surrounding stem cell research and its applications
have made this a difficult challenge," they wrote. "However, the
stakes are too high not to take a united stance."
(Reporting by Kate Kelland, editing by John Stonestreet)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|